KA801: pMVP (L3-L2) HA tag + pA; CMV::eGFP-P2A-TETa-pA
(Plasmid
#121800)
-
PurposepMVP L3-L2 entry plasmid, contains HA tag-polyA + CMV-eGFP-P2A-TETa-polyA for 3- or 4-component MultiSite Gateway Pro assembly. Adds C-term HA tag to gene plus downstream CMV-driven GFP-P2A-TETa
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 121800 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepDONR221 P3-P2
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 2555
-
Vector typeSynthetic Biology ; pMVP Gateway Entry Plasmid
-
Selectable markerseGFP
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameHA epitope tag-polyA + CMV::eGFP-P2A-TETa-polyA
-
SpeciesSynthetic
-
Insert Size (bp)2936
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer M13F
- 3′ sequencing primer M13R (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
TETa sequence derived from Tet-On Advanced system (Clontech)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
KA801: pMVP (L3-L2) HA tag + pA; CMV::eGFP-P2A-TETa-pA was a gift from Christopher Newgard (Addgene plasmid # 121800 ; http://n2t.net/addgene:121800 ; RRID:Addgene_121800) -
For your References section:
Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing. Haldeman JM, Conway AE, Arlotto ME, Slentz DH, Muoio DM, Becker TC, Newgard CB. Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286. 10.1093/nar/gky1286 PubMed 30590691